ES2093112T3 - Nuevo factor neurotrofico. - Google Patents

Nuevo factor neurotrofico.

Info

Publication number
ES2093112T3
ES2093112T3 ES91918727T ES91918727T ES2093112T3 ES 2093112 T3 ES2093112 T3 ES 2093112T3 ES 91918727 T ES91918727 T ES 91918727T ES 91918727 T ES91918727 T ES 91918727T ES 2093112 T3 ES2093112 T3 ES 2093112T3
Authority
ES
Spain
Prior art keywords
neurotrophic factor
designated
useful
new neurotrophic
diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91918727T
Other languages
English (en)
Inventor
Arnon Rosenthal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/587,707 external-priority patent/US5364769A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2093112T3 publication Critical patent/ES2093112T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTAN UN NUEVO POLIPEPTIDO, DESIGNADO FACTOR-4 NEUROTROFICO (NT-4), QUE HA SIDO INDENTIFICADO MEDIANTE AMPLIFICACION PCR DEL DNA GENOMICO HUMANO. SE SUMINISTRA ACIDO NUCLEICO QUE CODIFICA EL NT-4 UTIL EN DIAGNOSTICOS Y EN LA PREPARACION RECOMBINANTE DEL NT-4. TAMBIEN SE PRESENTAN ACIDOS NUCLEICOS QUE CODIFICAN VARIANTES DE SECUENCIAS DE AMINOACIDOS QUE SE PRODUCEN NATURALMENTE DEL NT-4, DESIGNADAS NT-4(BETA), NT4GAMMA, Y NT-4(DELTA). LOS FACTORES NEUROTROFICOS DE LA INVENCION SON UTILES EN EL TRATAMIENTO DE CELULAS NERVIOSAS Y EN PRUEBAS DE DIAGNOSTICO.
ES91918727T 1990-09-25 1991-09-24 Nuevo factor neurotrofico. Expired - Lifetime ES2093112T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/587,707 US5364769A (en) 1990-09-25 1990-09-25 Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US64848291A 1991-01-31 1991-01-31

Publications (1)

Publication Number Publication Date
ES2093112T3 true ES2093112T3 (es) 1996-12-16

Family

ID=27080108

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91918727T Expired - Lifetime ES2093112T3 (es) 1990-09-25 1991-09-24 Nuevo factor neurotrofico.

Country Status (11)

Country Link
US (2) US5830858A (es)
EP (1) EP0550665B1 (es)
JP (5) JPH06501617A (es)
AT (1) ATE140966T1 (es)
AU (1) AU654302B2 (es)
CA (1) CA2092567C (es)
DE (1) DE69121208T2 (es)
DK (1) DK0550665T3 (es)
ES (1) ES2093112T3 (es)
GR (1) GR3021371T3 (es)
WO (1) WO1992005254A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
EP0550665B1 (en) * 1990-09-25 1996-07-31 Genentech, Inc. Novel neurothrophic factor
WO1992020797A1 (en) * 1991-05-20 1992-11-26 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
CA2109598A1 (en) * 1991-05-21 1992-11-26 Finn Hallbook Therapeutic and diagnostic methods based on neurotrophin-4- expression
PT100580A (pt) * 1991-06-12 1993-09-30 Regeneron Pharma Producao e recuperacao de neurotrofinas recombinantes
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
AU4535993A (en) * 1992-06-12 1994-01-04 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
DK0662146T3 (da) * 1992-09-03 2000-11-13 Univ California Dorsalvævpåvirkende faktor og præparat
US5843775A (en) * 1992-09-03 1998-12-01 Regeneron Pharmaceuticals, Inc. Human dorsal tissue affecting factor (noggin) and nucleic acids encoding same
US5470719A (en) * 1994-03-18 1995-11-28 Meng; Shi-Yuan Modified OmpA signal sequence for enhanced secretion of polypeptides
AU3564595A (en) * 1994-09-12 1996-03-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Biologically active molecules derived from neurotrophins
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
NZ335207A (en) 1996-11-15 2000-09-29 Genentech Inc Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin
CN1250379A (zh) 1997-01-23 2000-04-12 住友制药株式会社 糖尿病治疗剂
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7037493B2 (en) * 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
GB0024550D0 (es) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
US7112668B2 (en) 2001-01-23 2006-09-26 Curagen Corporation Polypeptides and nucleic acids encoded thereby
WO2002081517A2 (en) * 2001-01-19 2002-10-17 Curagen Corporation Novel polypeptides and nucleic acids encoded thereby
EP1377306A1 (en) * 2001-03-09 2004-01-07 Dyax Corp. Serum albumin binding moieties
EP1262188A1 (en) * 2001-05-22 2002-12-04 Centre National De La Recherche Scientifique (Cnrs) Improved neuronal gene transfer
WO2003070189A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
US20040071705A1 (en) * 2002-06-21 2004-04-15 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
CA2637707A1 (en) * 2006-02-02 2007-08-09 Rinat Neuroscience Corporation Methods for treating obesity by administering a trkb antagonist
CN101400367A (zh) * 2006-02-02 2009-04-01 瑞纳神经科学公司 施用trkb激动剂治疗不希望的重量减轻或进食障碍的方法
KR20090091181A (ko) * 2006-12-20 2009-08-26 리나트 뉴로사이언스 코퍼레이션 자가면역 장애의 치료를 위한 티로신 수용체 키나아제 ｂ 작용제
WO2010086828A2 (en) * 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
EP4678236A3 (en) 2018-03-29 2026-04-08 MyNeuroCure Oy C-terminal cdnf and manf fragments, pharmaceutical compositions comprising same and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3113963A1 (de) * 1981-04-07 1982-10-21 Günter Horst 7927 Sontheim Röhm "vorrichtung zum absaugen von bohrmehl an der bohrstelle eines bohrers"
US4699875A (en) * 1982-11-24 1987-10-13 Baylor College Of Medicine Diagnosis of amyotrophic lateral sclerosis by neurotrophic factors
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
EP0550665B1 (en) * 1990-09-25 1996-07-31 Genentech, Inc. Novel neurothrophic factor
WO1992020797A1 (en) * 1991-05-20 1992-11-26 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
CA2109598A1 (en) * 1991-05-21 1992-11-26 Finn Hallbook Therapeutic and diagnostic methods based on neurotrophin-4- expression
PT100580A (pt) * 1991-06-12 1993-09-30 Regeneron Pharma Producao e recuperacao de neurotrofinas recombinantes
AU4535993A (en) * 1992-06-12 1994-01-04 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression

Also Published As

Publication number Publication date
DE69121208D1 (de) 1996-09-05
DK0550665T3 (da) 1996-12-02
ATE140966T1 (de) 1996-08-15
JPH06501617A (ja) 1994-02-24
CA2092567A1 (en) 1992-03-26
US6037320A (en) 2000-03-14
GR3021371T3 (en) 1997-01-31
DE69121208T2 (de) 1997-01-23
AU8756491A (en) 1992-04-15
WO1992005254A1 (en) 1992-04-02
JP2003159083A (ja) 2003-06-03
CA2092567C (en) 2007-07-03
JP2006087434A (ja) 2006-04-06
EP0550665A1 (en) 1993-07-14
EP0550665B1 (en) 1996-07-31
AU654302B2 (en) 1994-11-03
US5830858A (en) 1998-11-03
JP2004344175A (ja) 2004-12-09
JP2007209349A (ja) 2007-08-23

Similar Documents

Publication Publication Date Title
DK0550665T3 (da) Ny neurotrofisk faktor
DK163187C (da) Fremgangsmaader til fremstilling af humant immuninterferon (gamma-interferon) samt dna-fragmenter, rekombinante klonings- og udtrykkelsesvektorer og rekombinante mikroorganismer og cellekulturer til anvendelse herved
NZ218332A (en) Il-4(interleukin-4), recombinant production, dna, vectors and pharmaceutical composition
ZA859437B (en) Dna sequence encoding a hirudin-like protein and process for preparing such protein
EP0962531A3 (en) Interferon-gamma production inducing isolated polypeptide fragment and an isolated DNA fragment encoding said polypeptide
DK0506574T3 (da) Protein med aktivitet af cytokintype, rekombinant-DNA, der koder for dette protein, celler og transformerede mikroorganismer
FI98829B (fi) Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
DK239383D0 (da) Mikrobiologisk fremstillede alfa-og beta-interferoner, dna-sekvenser, der koder for disse interferoner, mikroorganismer, som indeholder denne genetiske information, og fremgangsmade til deres fremstilling
DE69434839D1 (de) Transferrin-rezeptor gene von haemophilus
DK568587D0 (da) Dna fragmenter indeholdende alkalisk cellulasegen, rekombinante plasmider indeholdende disse dna fregmenter og rekombinante mikroorganismer
DK127786D0 (da) Fremgangsmaade til fremstilling af tgf-beta, dna og mrna, som koder for tgf-beta, samt replicerbare vektorer omfattende dna'en og vaertscellerindeholdende vektorerne
IL88151A (en) Interleukin-7 protein, dna sequences encoding it, its preparation and compositions containing it
AU8223387A (en) Horse gamma-interferon
ATE481489T1 (de) Für den export verzweigtkettiger aminosäuren kodierende nukleotidsequenzen, verfahren zu deren isolierung und ihre verwendung
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
ATE61631T1 (de) Gen fuer ein protein mit insektizider wirkung.
DE3853693D1 (de) DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung.
DK595187A (da) Minactivin og fremgangsmaade til fremstilling deraf
ZA95968B (en) Interferon alpha/beta binding protein its preparation and use
EP0960935A4 (en) NEW CXC MURIN CHIMIOKIN RECEPTOR
MX9702205A (es) Gen de la galactocinasa humana.
DK56995A (da) Rekombinante lymphotoxin-varianter

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 550665

Country of ref document: ES